172 related articles for article (PubMed ID: 23482607)
21. Up-regulation of ERM/ETV5 correlates with the degree of myometrial infiltration in endometrioid endometrial carcinoma.
Planagumà J; Abal M; Gil-Moreno A; Díaz-Fuertes M; Monge M; García A; Baró T; Xercavins J; Reventós J; Alameda F
J Pathol; 2005 Dec; 207(4):422-9. PubMed ID: 16175655
[TBL] [Abstract][Full Text] [Related]
22. MMP-2, TIMP-1, E-cadherin, and beta-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium.
Shaco-Levy R; Sharabi S; Piura B; Sion-Vardy N
Acta Obstet Gynecol Scand; 2008; 87(8):868-74. PubMed ID: 18607832
[TBL] [Abstract][Full Text] [Related]
23. Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer.
Sasaki M; Dharia A; Oh BR; Tanaka Y; Fujimoto S; Dahiya R
Cancer Res; 2001 Jan; 61(1):97-102. PubMed ID: 11196205
[TBL] [Abstract][Full Text] [Related]
24. Membrane expression of the death ligand trail receptors DR4 and DR5 in the normal endometrium, endometrial atypical hyperplasia and endometrioid endometrial cancer.
Gottwald L; Szwalski J; Piekarski J; Pasz-Walczak G; Kubiak R; Spych M; Suzin J; Tyliński W; Sęk P; Jeziorski A
J Obstet Gynaecol; 2013 Jul; 33(5):512-8. PubMed ID: 23815209
[TBL] [Abstract][Full Text] [Related]
25. Expression of orexin receptors 1 (OX1R) and 2 (OX2R) in the porcine hypothalamus during the oestrous cycle.
Kaminski T; Smolinska N; Nitkiewicz A; Przala J
J Physiol Pharmacol; 2010 Jun; 61(3):363-71. PubMed ID: 20610868
[TBL] [Abstract][Full Text] [Related]
26. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers.
Xiong Y; Dowdy SC; Xue A; Shujuan J; Eberhardt NL; Podratz KC; Jiang SW
Gynecol Oncol; 2005 Mar; 96(3):601-9. PubMed ID: 15721400
[TBL] [Abstract][Full Text] [Related]
27. PINCH protein expression in normal endometrium, atypical endometrial hyperplasia and endometrioid endometrial carcinoma.
Zhang HZ; Li XH; Zhang X; Zhang ZY; Meng YL; Xu SW; Zheng Y; Zhu ZL; Cui DS; Huang LX; Yan BY; Sun XF
Chemotherapy; 2010; 56(4):291-7. PubMed ID: 20714146
[TBL] [Abstract][Full Text] [Related]
28. Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U.
Yang X; Wang CC; Lee WYW; Trovik J; Chung TKH; Kwong J
Cancer Lett; 2018 Jan; 413():23-34. PubMed ID: 29107108
[TBL] [Abstract][Full Text] [Related]
29. A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma.
Planagumà J; Díaz-Fuertes M; Gil-Moreno A; Abal M; Monge M; García A; Baró T; Thomson TM; Xercavins J; Alameda F; Reventós J
Cancer Res; 2004 Dec; 64(24):8846-53. PubMed ID: 15604243
[TBL] [Abstract][Full Text] [Related]
30. FGF2 transcript levels are positively correlated with EGF and IGF-1 in the malignant endometrium.
Soufla G; Sifakis S; Spandidos DA
Cancer Lett; 2008 Feb; 259(2):146-55. PubMed ID: 18006148
[TBL] [Abstract][Full Text] [Related]
31. ERM/ETV5 and RUNX1/AML1 expression in endometrioid adenocarcinomas of endometrium and association with neoplastic progression.
de Sousa VP; Chaves CB; Huguenin JF; Moreira FC; de Reis BS; Chimelli L; Bergmann A; Simão Tde A; Pinto LF
Cancer Biol Ther; 2014 Jul; 15(7):888-94. PubMed ID: 24756106
[TBL] [Abstract][Full Text] [Related]
32. Hypermethylation in the p16 promoter region in the carcinogenesis of endometrial cancer in Japanese patients.
Yanokura M; Banno K; Susumu N; Kawaguchi M; Kuwabara Y; Tsukazaki K; Aoki D
Anticancer Res; 2006; 26(2A):851-6. PubMed ID: 16619479
[TBL] [Abstract][Full Text] [Related]
33. Expression of human prepro-orexin and signaling characteristics of orexin receptors in the male reproductive system.
Karteris E; Chen J; Randeva HS
J Clin Endocrinol Metab; 2004 Apr; 89(4):1957-62. PubMed ID: 15070969
[TBL] [Abstract][Full Text] [Related]
34. Expression of orexin receptors in the pituitary.
Kaminski T; Smolinska N
Vitam Horm; 2012; 89():61-73. PubMed ID: 22640608
[TBL] [Abstract][Full Text] [Related]
35. Promoter hypermethylation contributes to TIMP3 down-regulation in high stage endometrioid endometrial carcinomas.
Catasus L; Pons C; Muñoz J; Espinosa I; Prat J
Histopathology; 2013 Mar; 62(4):632-41. PubMed ID: 23379820
[TBL] [Abstract][Full Text] [Related]
36. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
37. Inhibin-α subunit expression in uterine endometrioid adenocarcinomas and endometrial cancer cell lines: a potential prognostic factor.
Mylonas I
Int J Mol Med; 2011 Mar; 27(3):309-18. PubMed ID: 21174065
[TBL] [Abstract][Full Text] [Related]
38. Orexin receptor expression in human adipose tissue: effects of orexin-A and orexin-B.
Digby JE; Chen J; Tang JY; Lehnert H; Matthews RN; Randeva HS
J Endocrinol; 2006 Oct; 191(1):129-36. PubMed ID: 17065396
[TBL] [Abstract][Full Text] [Related]
39. Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells.
Goto T; Takano M; Albergaria A; Briese J; Pomeranz KM; Cloke B; Fusi L; Feroze-Zaidi F; Maywald N; Sajin M; Dina RE; Ishihara O; Takeda S; Lam EW; Bamberger AM; Ghaem-Maghami S; Brosens JJ
Oncogene; 2008 Jan; 27(1):9-19. PubMed ID: 17599040
[TBL] [Abstract][Full Text] [Related]
40. Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma.
Jiang XF; Tang QL; Shen XM; Li HG; Chen LH; Wang XY; Luo X; Lin ZQ; Jiang GY
Pathol Res Pract; 2012 Dec; 208(12):730-5. PubMed ID: 23122929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
